Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 2UNKNOWN 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 274Thoracic 14Head & Neck 9Tumor-Agnostic 6Other solid neoplasm 5Breast 3Genitourinary 2NET 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 2Breast Cancer Recurrent 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × S 1 (combination) × Breast × Clear all
NCT02947061 2016-10-31

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
300 enrolled
Breast

Breast Cancer Recurrent

NCT00438100 2015-05-29

Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer

Japan Breast Cancer Research Network

Phase 2 Completed
142 enrolled 4 charts
Breast

Breast Neoplasms

NCT01849380 2013-05-08

Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer

Shandong University

Phase 4 Unknown
240 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡